Management buy-out at Kone Instruments
This article was originally published in Clinica
A consortium of Finnish investors is to purchase Kone Instruments from Kone Corp (Finland). The diagnostic testing business became available when the parent decided to focus on its core elevator activities. The consortium, which includes the Finnish National Fund for Research and Development, SISTRA, and management, will retain the Kone Instruments name.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.